GHASSAN ZALZALEH MD NPI 1992704035

NPI Details

Ghassan Zalzaleh, MD is a hematology and oncology internal medicine in Oak Lawn, IL with 38 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Ghassan Zalzaleh, MD NPI is 1992704035. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

4400 W 95TH ST
SUITE 311
OAK LAWN, IL
ZIP 60453-654
Phone: (708) 424-9710
Fax: (708) 424-4331

The NPI 1992704035 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Collection of blood sample from implanted device (HCPCS:36591)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Unclassified drugs (HCPCS:J3490)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Ct scan of chest with contrast (HCPCS:71260)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Ct scan of chest without contrast (HCPCS:71250)
• Drawing of blood for a medical problem (HCPCS:99195)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Piflufolastat f-18, diagnostic, 1 millicurie (HCPCS:A9595)

The enumeration date for this NPI number is 7/20/2005 and was last updated on 7/10/2015.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.